DV
Dividend Vision

DWTX — Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. (DWTX)

Total return is -99.5% over the past 5.7 years, 225.1 points behind SPY at 125.6%. Its deepest 1-year drawdown was 83.1%.

Dogwood Therapeutics is a development-stage biotechnology company focused on treating pain and fatigue-related disorders, with lead candidates including IMC-1 for fibromyalgia, Halneuron for chemotherapy-induced neuropathic pain, and several other drug candidates in clinical and preclinical development. The company does not currently distribute dividends. This stock appeals to investors seeking exposure to early-stage biotechnology development with a focus on pain management therapies, though it carries the risks inherent to companies in pre-revenue or early clinical stages.

DWTX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/17/2020
Last close
$2.15
Market cap
$46,408,780
Average volume
105800.0
Beta
1.714
Payout ratio
0.0
P/E ratio
1.1795
Forward P/E
0.0
EPS
$1.17